Rothschild & Co Redburn Cuts Moderna Rating to Sell
Moderna was downgraded by Rothschild & Co Redburn from neutral to sell, while Brookline Capital Markets reiterated a buy rating. Moderna reported quarterly EPS of -$1.97, slightly above the expected -$2.03, and revenue was up 2.1% year over year. The article also notes share ownership changes and insider holdings.